First degrader of lipid kinase PIP4K2C shows promise in colon cancer
Larkspur Biosciences has announced the discovery of LRK-4189, a first-in-class degrader of the lipid kinase PIP4K2C for the treatment of microsatellite stable (MSS) colorectal cancer (CRC) and other solid tumours.
The announcement was made at ACS Fall 2025, a meeting of the American Chemical Society in Washington, DC.
Cancer cells maintain their fitness by developing survival adaptations that foster escape from intrinsic and extrinsic mechanisms of cell death in conditions of stress.
Phosphatidylinositol 5-phosphate 4-kinase, type II, gamma (PIP4K2C) is a lipid kinase associated with poor outcomes in a range of cancers including CRC and breast cancers. PIP4K2C is co-opted by cancer cells to increase their fitness by evading immune surveillance and adapting to stress.
In vivo, LRK-4189 has demonstrated dose dependent PKPD with single agent efficacy in multiple models of CRC and synergy with first-line standard of care chemotherapy.
In primary human CRC patient-derived spheroids, 50% of patient samples responded to LRK-4189 with a preferential response in MSS CRC, which compares favourably to benchmark cetuximab in the same platform (35%).
Larkspur expects to initiate a Phase 1 clinical trial in Q4 2025.
“Genetic studies have long highlighted PIP4K2C as a key player in cancer stress adaptation, but its extremely low kinase activity made it resistant to conventional inhibition approaches,” said Catherine Sabatos-Peyton, CEO of Larkspur Biosciences. “With our novel degrader, LRK-4189, we’ve finally unlocked this critical pathway. By reducing cancer cell fitness, triggering intrinsic apoptosis, and engaging the immune system to clear residual tumour cells, LRK-4189 has the potential to overcome the limitations of earlier therapies. We’re excited to advance this promising therapy to the clinic later this year.”
Diana Turner, Senior Digital Content Editor, DDW
